Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

There May Be More Moves Involving Salix Before The Year's Done

There has been ample M&A activity in the drug sector, with companies like Valeant (NYSE:VRX), Endo International (NASDAQ:ENDP), and Actavis (ACT) all looking to add scale and exploit low interest rates and low tax rates. Salix (NASDAQ:SLXP) has been busy too, paying around $2.6 billion to acquire Santarus and adding scale in primary care and GI drugs. Salix's valuation suggests that investors may still be expecting more action, as Salix's focused portfolio and high effective tax rate could make it a player either as an acquirer seeking a tax inversion deal or a target.

A Messy Start To The Year

Salix's reported results for the first quarter were basically okay, but messier than investors...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details